Form 4: Inotiv Inc. Executive Adrian Hardy Receives 25,000 Restricted Stock Units

Inotiv Inc.'s Chief Commercial Officer, Adrian Hardy, was granted 25,000 restricted stock units (RSUs) on March 14, 2025, which will vest in full on March 14, 2027, subject to continued employment.

Summary

• Adrian Hardy, Chief Commercial Officer of Inotiv Inc., received a grant of 25,000 restricted stock units on March 14, 2025.
• These RSUs will vest in full on March 14, 2027, contingent upon Mr. Hardy's continued employment with the company.
• Following this transaction, Mr. Hardy beneficially owns 58,420 shares of Inotiv Inc. common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The RSU grant is a standard practice and indicates confidence in the executive's continued contributions. However, it's not a major event that would significantly impact the company's outlook.

Positives

• The grant of restricted stock units aligns the executive's interests with the long-term performance of the company.
• Continued employment is required for vesting, incentivizing the executive to remain with the company.

Risks

• The value of the restricted stock units is dependent on the future stock price of Inotiv Inc., which is subject to market fluctuations.
• If Adrian Hardy leaves the company before March 14, 2027, the unvested RSUs will be forfeited.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the RSU grant suggests an expectation of continued contributions from the executive.

Industry Context

Grants of restricted stock units are a common form of executive compensation in publicly traded companies, particularly in the biotech and pharmaceutical services industries. They are used to align executive incentives with shareholder value and encourage long-term commitment to the company.

Comparison to Industry Standards

• Executive compensation packages, including RSU grants, vary significantly across the pharmaceutical and biotechnology services industry.
• Companies like Charles River Laboratories and Envigo (prior to its acquisition) also utilize stock-based compensation as part of their executive pay structures.
• The size of the RSU grant is relative to the executive's role and the company's overall compensation strategy, which is often benchmarked against peer companies.

Stakeholder Impact

• Shareholders may view the RSU grant as a positive sign, aligning executive interests with long-term company performance.
• Employees may see the grant as a sign of stability and commitment to key personnel.

Key Dates